McDonald criteria

McDonald criteria are diagnostic criteria used in the diagnosis of multiple sclerosis (MS). These criteria are named after Ian McDonald, a British neurologist who played a significant role in their development.
History[edit]
The McDonald criteria were first published in 2001, with revisions made in 2005, 2010, and 2017. The aim of these criteria is to enable the diagnosis of MS in patients with a single clinical attack and positive magnetic resonance imaging (MRI) findings.
Criteria[edit]
The McDonald criteria incorporate clinical, radiological, and laboratory findings. The 2017 revision of the McDonald criteria includes the following:
- Evidence for at least two attacks of neurological dysfunction, with objective clinical evidence for at least one.
- Evidence for at least one attack of neurological dysfunction, with objective clinical evidence for at least two lesions.
- Evidence for dissemination in space (DIS) and time (DIT) on MRI, or a positive cerebrospinal fluid (CSF) analysis.
- No better explanation for the clinical presentation.
Use[edit]
The McDonald criteria are widely used in clinical practice and research settings for the diagnosis of MS. They have been shown to be highly sensitive and specific for the diagnosis of MS.
Criticism[edit]
Despite their widespread use, the McDonald criteria have been criticized for their complexity and for the potential for over-diagnosis of MS.
See also[edit]
| Demyelinating diseases of the central nervous system | ||||||||
|---|---|---|---|---|---|---|---|---|
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
